The present study found that T2DM patients with MASLD and metabolic hyperferritinemia had higher markers of liver steatosis and fibrosis (with an almost four-fold higher risk of advanced fibrosis), worse long-term glycemic control, and higher insulin resistance. The gene discussed is INS; the disease is type 2 diabetes mellitus.